New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease
Dapagliflozin is cost-effective for chronic kidney disease compared with standard of care, in the UK, Germany, and Spain, despite the fact that the drug has high acquisition costs, finds a new analysis.